Benedikt Timmerman

Benedikt TIMMERMAN has over 25 years of experience building and leading businesses in life sciences. His career testifies of his entrepreneurial skills at recognizing talent, building strong teams and uniting the financial resources needed for preclinical and clinical drug development programs.

Benedikt is currently a part-time Venture Partner at IRDI SORIDEC Gestion and a board member of such companies as Cell-Easy and Horama. At IRDI SORIDEC Gestion, he advises the firm on investment opportunities in the Health Care sector and serves on the board of various portfolio companies, including Ixaltis, Antabio and Aelis Farma. From 2018 to 2020, as a senior business advisor to Brainvectis, Benedikt paved the way to the sale of all of the company’s shares to Asklepios Biotherapeutics (USA), in April 2020. As founder and CEO of BT Pharma in 2001, which became Genticel in 2010, he raised over €34 million in venture funding. In 2014, he took the company public on Euronext in Paris and Brussels, raising another €34.7 million in the process. In 2017, he oversaw the merger of Genticel and Genkyotex (GKTX). Previously, Benedikt held senior R&D and corporate licensing positions at NOVARTIS (1996 – 2000) and SANDOZ (1991 – 1996).

Benedikt holds a master’s degree in Biology and a Ph.D. in Genetics from the University of Ghent, Belgium, as well as an M.B.A. from INSEAD, Fontainebleau, France.